The phrase "availability of cost" is not correct and may cause confusion in written English.
It is typically used when discussing the accessibility or presence of pricing information for a product or service.
Example: "Before making a decision, I need to check the availability of cost for the different options we are considering."
Alternatives: "cost accessibility" or "pricing availability".
However, limited availability of cost data often renders such analyses either incomplete or implausible.
273, amended analysis identically, substituting "Availability of cost and pricing records" for "Cost and price management" in item 2406 and adding items 2397b, 2397c, 2408, and 2409.
Though the world is suffering from energy crisis, a large amount of low grade heat (temperature lower than 100̊C) is being wasted for the lack of availability of cost effective technology.
Ten years after the start of the European Data Collection Framework the availability of cost indicators for assessing the economic status of fisheries or bio-economic modelling is still deficient.
Many factors will drive the faster pace of growth, among them the expansion of online marketplaces; a proliferation of on-demand talent; the availability of cost effective online advertising; access to better business infrastructure, such as cloud computing; and the growing abundance of useful data, Intuit found.
Making progress in this area requires dealing with three main obstacles: (1) data availability, as there are few available standardized measures of skill; (2) methodological issues that involve ascertaining the causal effects of each input; and (3) availability of cost information, that is, data that render cost-effectiveness comparisons feasible.
Recent enhancements in visual instrumentation with the availability of cost-effective hardware and software products make the digital imaging techniques a viable tool to replace direct strain or displacement measurement methods in engineering applications.
The market development of plasmid biopharmaceuticals for gene therapy and DNA vaccination applications is critically dependent on the availability of cost-effective manufacturing processes capable of delivering large amounts of high-quality plasmid DNA (pDNA) for clinical trials and commercialization.
We aimed to evaluate the time for trastuzumab reimbursement approval and its association to health expenditure, to health policy performance, to the availability of cost-effectiveness studies and to breast cancer outcome.
Despite the availability of cost-effective and well-tolerated treatments that can reduce fracture risk, only 23% of women ages 67 or older who have an osteoporosis-related fracture receive either a bone mineral density test or a prescription for an osteoporosis drug in the six months after the fracture.
While it is recognized that the main driver for regulation is the potential risk to human health and that this risk is currently being examined by a number of health-based organizations, the actual form of any regulation would likely be dependent upon the availability of cost-effective control technologies.
